Serum high-sensitivity C-reactive protein as a biomarker in patients with metabolic syndrome: Evidence-based study with 7284 subjects

European Journal of Clinical Nutrition

Volumn 70, Issue 11, 2016, Pages 1298-1304

  Mirhafez, S R ^a   Ebrahimi, M ^b,c   Saberi Karimian, M ^c   Avan, A ^c   Tayefi, M ^c   Heidari Bakavoli, A ^b   Parizadeh, M R ^c   Moohebati, M ^b   Azarpazhooh, M R ^b,c   Esmaily, H ^d   Nematy, M ^c   Safarian, M ^c   Ferns, G A ^e   Ghayour Mobarhan, M ^b,c  

^a NEYSHABUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRACE ELEMENT; TRIACYLGLYCEROL; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIETARY INTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MACRONUTRIENT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; ANTHROPOMETRY; BLOOD; EVALUATION STUDY; EVIDENCE BASED MEDICINE; METABOLISM; QUESTIONNAIRE;

ADULT; AGED; ANTHROPOMETRY; BIOMARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME; MIDDLE AGED; SURVEYS AND QUESTIONNAIRES; TRIGLYCERIDES;

EID: 84979598050     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2016.111     Document Type: Article

References (42)

1. Zuliani G, Volpato S, Galvani M, Blè A, Bandinelli S, Corsi AM et al. Elevated C-reactive protein levels and metabolic syndrome in the elderly: The role of central obesity data from the InChianti study. Atherosclerosis 2009; 203: 626-632.
2. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult US population, 1999-2010. J Am Coll Cardiol 2013; 62: 697-703.
3. Odum EP, Orluwene CG. Metabolic syndrome prevalence in healthy individuals in University Of Port Harcourt Teaching Hospital (Upth), Port Harcourt. IOSR-JDMS 2013; 10: 17-22.
4. Fakhrzadeh H, Ebrahimpour P, Pourebrahim R, Heshmat R, Larijani B. Metabolic syndrome and its associated risk factors in healthy adults: A population-based study in Iran. Metab Syndr Relat Disord 2006; 4: 28-34.
5. Ostovaneh MR, Zamani F, Sharafkhah M, Ansari-Moghaddam A, Akhavan Khaleghi N, Saeedian FS et al. Prevalence of Metabolic Syndrome in Amol and Zahedan, Iran: A population based study. Arch Iran Med 2014; 17: 477-482.
6. Pdure L, Ignat IS, Eanu I, Hurjui J. Prevalence of metabolic syndrome in a population of transport workers-prospective study. Rev Med Chir Soc Med Nat Iasi 2011; 115: 1048-1051.
7. Mirhosseini N-Z, Mohd Yusoff NA, Shahar S, Parizadeh SMR, Ghayour Mobarhen M, Shakery MT. Prevalence of the metabolic syndrome and its influencing factors among adolescent girls in Mashhad, Iran. Asia Pac J Clin Nutr 2009; 18: 131.
8. Fernández RP, Kaski JC. Interleukin-10 and coronary disease. Rev Esp Cardiol 2002; 55: 738-750.
9. De Ferranti SD, Gauvreau K, Ludwig DS, Newburger JW, Rifai N. Inflammation and changes in metabolic syndrome abnormalities in US adolescents: findings from the 1988-1994 and 1999-2000 National Health and Nutrition Examination Survey. Clin Chem 2006; 52: 1325-1330.
10. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H et al. Association between C-reactive protein and features of the metabolic syndrome: A population-based study. Diabetes Care 2000; 23: 1835-1839.
11. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial. JAMA 2004; 292: 1440-1446.
12. Pepys M, Rowe I, Baltz ML. C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Path 1985; 27: 83-111.
13. Haverkate E, Thompson SG, Pyke SD, Gallimore JR, Group MBP. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-466.
14. González AS, Guerrero DB, Soto MB, Díaz SP, Martinez-Olmos M, Vidal O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr 2006; 60: 802-809.
15. Wang L, Zheng B, Zhao H, Du P, Sun A, Hua K et al. Adducin gene G614T polymorphisms in essential hypertension patients with high low density lipoprotein (LDL) levels. Indian J Med Res 2014; 139: 273.
16. Kang ES, Kim HJ, Ahn CW, Park CW, Cha BS, Lim SK et al. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract 2005; 69: 151-159.
17. Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SM, Heidari-Bakavoli AR et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health 2015; 60: 561-572.
18. Zomorrodian D, Khajavi-Rad A, Avan A, Ebrahimi M, Nematy M, Azarpazhooh MR et al. Metabolic syndrome components as markers to prognosticate the risk of developing chronic kidney disease: evidence-based study with 6492 individuals. J Epidemiol Commun Health 2015; 69: 594-598.
19. Ghayour-Mobarhan M, Taylor A, Lamb DJ, Ferns GA. Association between indices of body mass and antibody titres to heat-shock protein-60,-65 and-70 in healthy Caucasians. Int J Obes (Lond) 2007; 31: 197-200.
20. Mirhafez SR, Pasdar A, Avan A, Esmaily H, Moezzi A, Mohebati M et al. Cytokine and growth factor profiling in patients with the metabolic syndrome. Br J Nutr 2015; 113: 1911-1919.
21. Emamian M, Avan A, Pasdar A, Mirhafez SR, Sadeghzadeh M et al. The lipoprotein lipase S447X and cholesteryl ester transfer protein rs5882 polymorphisms and their relationship with lipid profile in human serum of obese individuals. Gene 2015; 558: 195-199.
22. Guerrero-Romero F, Rodriguez-Moran M. Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab 2003; 29: 65-71.
23. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14719 initially healthy American women. Circulation 2003; 28: 391-397.
24. Riaz M, Fawwad A, Hydrie MZI, Basit A, Shera AS. Is there any association of serum high-sensitivity C-reactive protein with various risk factors for metabolic syndrome in a healthy adult population of karachi, pakistan Metab Syndr Relat Disord 2011; 9: 177-182.
25. Chou Y-Y, Sheu WH, Tang Y-J, Chen Y-M, Liao S-C, Chuang Y-W et al. Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan. Arch Gerontol Geriatr 2009; 49: S41-S45.
26. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: A randomized, controlled clinical trial. Ann Int Med 2000; 133: 111-122.
27. Chen H, Cowan MJ, Hasday JD, Vogel SN, Medvedev AE. Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1 R-associated kinase, p38, and NF-kB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J Immunol 2007; 179: 6097-6106.
28. Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: The central role of interleukin-6. Eur Heart J 2000; 21: 1574-1583.
29. Laurell C-B, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. J Clin Endocrinol Metab 1979; 49: 719-725.
30. Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and otherhepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 2008; 93: 1702-1710.
31. Kurtz Emily G, Ridker Paul M, Rose Lynda M, Cook Nancy R, Everett Brendan M, Buring Julie E. et al. Oral postmenopausal hormone therapy, C-reactive protein and cardiovascular outcomes. Menopause 2011; 18: 23-29.
32. Vendrame F, Gottlieb PA. Prediabetes: prediction and prevention trials. Endocrinol Metab Clin North Am 2004; 33: 75-92.
33. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
34. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-1600.
35. Valle Gottlieb MG, da Cruz IBM, Duarte MM, Moresco RN, Wiehe M, Schwanke CHA et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 2010; 95: 586-591.
36. Zhao Y, Yang K, Wang F, Liang Y, Peng Y, Shen R et al. Associations between metabolic syndrome and syndrome components and retinal microvascular signs in a rural Chinese population: The Handan Eye Study. Graefe's Arch Clin Exp Ophthalmol 2012; 250: 1755-1763.
37. Shimomura I, Funahasm T, Takahashi M, Maeda K, Kotani K, Nakamura T et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obeisty. Nat Med 1996; 2: 800-803.
38. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323.
39. Manjunath D, Uthappa CK, Kattula SR, Allam RR, Chava N, Oruganti G. Metabolic syndrome among urban indian young adults: prevalence and associated risk factors. Metab Synd Relat Disord 2014; 12: 381-389.
40. Rensburg MA, Matsha T, Hoffmann M, Hassan S, Erasmus RT, Rensburg M. Distribution and association of hs-CRP with cardiovascular risk variables of metabolic syndrome in adolescent learners. Lab Med 2012; 1: 1.
41. Shea J, King M, Yi Y, Gulliver W, Sun G. Body fat percentage is associated with cardiometabolic dysregulation in BMI-defined normal weight subjects. Nutr Metab Cardiovasc Dis 2012; 22: 741-747.
42. Mosazadeh H, Sedghianifar A, Bani adam T. Reliability and Validity of satisfaction questionnaire of subjects referred to urban health care centers. Quart J Orumieh Faculty Nurs Midwife 2010; 8: 246-253.